Lecanemab, sold under the name Leqembi, is a monoclonal antibody therapy for Alzheimer's disease that clears toxic amyloid ...

In an unprecedented large-scale study, researchers have mapped out the first molecular events that cause harmful protein buildups in the brain of people with Alzheimer's disease. "By measuring the ...

TOKYO, Feb 14, 2025 - (JCN Newswire) - - Oita University and Eisai Co., Ltd. (Eisai) announced today the development of a machine learning model to predict amyloid beta(1)(Abeta) accumulation in the ...

Researchers have uncovered a new factor that could contribute to Alzheimer’s disease development. A study by Harvard Medical School has identified low lithium levels in the brain as a possible trigger ...

Medications like lecanemab (Leqembi) and donanemab (Kisunla) target amyloid plaques in the brain that build up due to Alzheimer’s disease. They may help slow disease progression for people in the ...

Experimental drug NU-9 -- a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) -- improves ...